Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.

Abstract:

:In a randomized double-blind study, 20 parkinsonian patients (suffering from the disease for 2-18 years), chronically treated with levodopa (500-750 mg/day for 0.5-12 years), received terguride (1 mg b.i.d.) or placebo for 4 weeks. Growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), and insulin-like growth factor (IGF-I) secretions were studied before and after the morning dose of levodopa (250 mg p.o.), both before and at the end of study period. At the beginning of the study, basal hormonal levels were within normal limits, and levodopa administration induced a significant suppression in PRL and TSH levels (both p < 0.01)) and a significant increase in GH (p < 0.01). The same results were observed at the end of the study period in the placebo group. Addition of terguride induced a significant suppression in basal PRL levels (p < 0.01), whereas levodopa-induced hormonal changes were unaffected. These data suggest that the hypothalamic dopaminergic function that controls anterior pituitary hormones is preserved in parkinsonian patients, regardless of both the duration of the disease and the long-term treatment with levodopa. The strong additional prolactin-lowering effect of terguride indicates long-lasting dopaminergic effects, as is already known from hyperprolactinemic conditions. The dopaminergic effects of levodopa on TSH, GH, and IGF-I secretion were unchanged by terguride treatment. The anti-dopaminergic effects of terguride observed in the motor system in animal studies, as well as in levodopa-induced dyskinesias in parkinsonian patients, could not be observed in the case of the dopaminergic control of anterior pituitary hormones under the conditions of this study.

journal_name

Clin Neuropharmacol

authors

Martignoni E,Horowski R,Liuzzi A,Costa A,Dallabonzana D,Cozzi R,Attanasio R,Rainer E,Nappi G

doi

10.1097/00002826-199619010-00006

subject

Has Abstract

pub_date

1996-02-01 00:00:00

pages

72-80

issue

1

eissn

0362-5664

issn

1537-162X

journal_volume

19

pub_type

临床试验,杂志文章,随机对照试验
  • Serotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report.

    abstract:BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000220

    authors: Jeon DG,Kim YW,Kim NY,Park JH

    更新日期:2017-07-01 00:00:00

  • Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

    abstract::The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-200101000-00007

    authors: Thomas A,Iacono D,Bonanni L,D'Andreamatteo G,Onofrj M

    更新日期:2001-01-01 00:00:00

  • Clinical pharmacology and mechanism of action of zonisamide.

    abstract::Antiepileptic drugs (AEDs) suppress seizures by selectively modifying the excitability of neurons and blocking seizure firing with minimal disturbance of nonepileptic activity. All AEDs have been shown to work by at least one of 3 main mechanisms of action: through modulation of voltage-gated ion channels, enhancement...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/wnf.0b013e3180413d7d

    authors: Biton V

    更新日期:2007-07-01 00:00:00

  • Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

    abstract::Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently appr...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200211000-00002

    authors: Richard IH,Justus AW,Greig NH,Marshall F,Kurlan R

    更新日期:2002-11-01 00:00:00

  • The reversibility of "permanent" tardive dyskinesia.

    abstract::Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198406000-00006

    authors: Klawans HL,Tanner CM,Barr A

    更新日期:1984-01-01 00:00:00

  • Diagnosis and assessment of age-associated memory impairment.

    abstract::Age-associated memory impairment (AAMI) is a diagnostic term applied to healthy persons greater than 50 years of age who have experienced a gradual decline in memory that lies within the boundaries of normality. Although the behavioral deficits associated with AAMI are modest in comparison to those associated with dem...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199013003-00009

    authors: Crook TH,Larrabee GJ,Youngjohn JR

    更新日期:1990-01-01 00:00:00

  • Knee Buckling (Negative Myoclonus) Associated With Clozapine: Reports on 3 Cases.

    abstract:BACKGROUND:Negative myoclonus is rarely seen in the clinical setting. It can be involved in some central nervous system pathologies. It has also been observed after antipsychotic treatment. CASE REPORTS:In this article, we will present 3 cases diagnosed with negative myoclonus in a 120-bed university-affiliated hospit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000370

    authors: Uzun Ö,Bolu A,Taşçi AB,Oğur B

    更新日期:2020-01-01 00:00:00

  • Paroxysmal dystonia responsive to anticholinergic drugs.

    abstract::A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198708000-00007

    authors: Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

    更新日期:1987-08-01 00:00:00

  • L-tyrosine pharmacotherapy of schizophrenia: preliminary data.

    abstract::The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199402000-00006

    authors: Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

    更新日期:1994-02-01 00:00:00

  • Preclamol and parkinsonian fluctuations.

    abstract::Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomo...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Pirtosek Z,Merello M,Carlsson A,Stern G

    更新日期:1993-12-01 00:00:00

  • Lithium and male sexual function in affective patients.

    abstract::The aim of the present study was to evaluate sexual function and behaviour in male patients who take lithium. Participants included 35 bipolar and schizoaffective men, aged 43.3 +/- 9.6 years, who were in euthymic state and were receiving lithium as the sole medical treatment. Eleven patients (31.4%) reported sexual d...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199619060-00005

    authors: Aizenberg D,Sigler M,Zemishlany Z,Weizman A

    更新日期:1996-12-01 00:00:00

  • Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.

    abstract::We report on a schizophrenic patient whose tardive dystonia, delusions, and auditory hallucinations showed remarkable concurrent improvement after replacing haloperidol with risperidone. The present finding suggests that the 5-hydroxytryptamine-2 (5-HT2) antagonistic action of risperidone has brought about the improve...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Yoshida K,Higuchi H,Hishikawa Y

    更新日期:1998-01-01 00:00:00

  • The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.

    abstract::We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199304000-00007

    authors: Keränen T,Gordin A,Harjola VP,Karlsson M,Korpela K,Pentikäinen PJ,Rita H,Seppälä L,Wikberg T

    更新日期:1993-04-01 00:00:00

  • Neurobiology and clinical pharmacology of obsessive-compulsive disorder.

    abstract::Obsessive-compulsive disorder (OCD) is a brain disorder with recognizable periods of onset, course, familial occurrence, epidemiology, phenomenology, and treatment response. Several manifestations of pathophysiology are beginning to be defined, although they may represent intermediate pathophysiology rather than prima...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200107000-00002

    authors: Micallef J,Blin O

    更新日期:2001-07-01 00:00:00

  • Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.

    abstract::Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200111000-00006

    authors: Giménez-Roldán S,Esteban EM,Mateo D

    更新日期:2001-11-01 00:00:00

  • Astroglial cells: glucocorticoid target cells in the brain.

    abstract::Glutamine synthetase (GS), an enzyme localized in astroglial cells in the brain, is directly implicated in brain detoxification. An ontogenic study of GS activity was performed in homogenates from four distinct brain areas in comparison with the respective astrocytes obtained in primary cultures. GS was induced by hyd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Tardy M,Rolland B,Fages C,Caldani M

    更新日期:1984-01-01 00:00:00

  • Rare neurodevelopmental abnormalities of sarcosinemia may involve glycinergic stimulation of a primed N-methyl-d-aspartate receptor.

    abstract::Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.WNF.0000236767.46526.1F

    authors: Deutsch SI,Rosse RB,Long KD,Gaskins B,Mastropaolo J

    更新日期:2006-11-01 00:00:00

  • No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease.

    abstract::We studied the effect of chronic bromocriptine cotherapy on levodopa kinetics in seven patients with Parkinson's disease who were receiving levodopa therapy. Plasma levodopa concentrations were measured after a standard oral levodopa fasting dose over a 5-hour period, on two different sessions, without and with bromoc...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199212000-00008

    authors: Contin M,Riva R,Martinelli P,Albani F,Baruzzi A

    更新日期:1992-12-01 00:00:00

  • Plasma-level response relationships with fluoxetine and zimelidine.

    abstract::The results of pharmacokinetic studies of two recent 5-HT uptake inhibitors, zimelidine and fluoxetine, have pointed to the inadequacy of open-dose rising studies for establishing the most appropriate dose of new antidepressants. High plasma concentrations of the active metabolites, norzimelidine and norfluoxetine, we...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199001001-00008

    authors: Montgomery SA,Baldwin D,Shah A,Green M,Fineberg N,Montgomery D

    更新日期:1990-01-01 00:00:00

  • An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.

    abstract:BACKGROUND:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong affinity for dopamine and serotonin receptors. Unlike first- and second-generation antipsychotics, it has agonist activity at GABA(A). OBJECTIVE:This is the first study to examine tolerability an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/WNF.0b013e3181f8d501

    authors: Anand R,Geffen Y,Vasile D,Dan I

    更新日期:2010-11-01 00:00:00

  • Investigating the efficacy of paroxetine in developmental stuttering.

    abstract:OBJECTIVES:Paroxetine has been reported to be useful for management of stuttering symptoms, but only a few reports have examined its effects. We have investigated the efficacy of paroxetine in a randomized, placebo-controlled study. METHODS:Five stuttering subjects received paroxetine at 20 mg once daily at night for ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0b013e31819817eb

    authors: Busan P,Battaglini PP,Borelli M,Evaristo P,Monti F,Pelamatti G

    更新日期:2009-07-01 00:00:00

  • A multicenter Italian study of amineptine (Survector 100).

    abstract::This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00002826-198912002-00006

    authors: Kemali D

    更新日期:1989-01-01 00:00:00

  • Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.

    abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200311000-00009

    authors: Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

    更新日期:2003-11-01 00:00:00

  • Effects of tandospirone on "5-HT1A receptor-associated symptoms" in patients with Machado-Josephe disease: an open-label study.

    abstract:BACKGROUND:We investigated the frequencies of the symptoms such as "ataxia, depression, insomnia, anorexia, and pain," that have been reported to be associated with 5-HT1A receptor, and the effect of tandospirone citrate (tandospirone: 5-HT1A agonist) in patients with Machado-Joseph disease (MJD). METHODS:Ten MJD pati...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200401000-00005

    authors: Takei A,Fukazawa T,Hamada T,Sohma H,Yabe I,Sasaki H,Tashiro K

    更新日期:2004-01-01 00:00:00

  • Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.

    abstract:OBJECTIVES:The units of different botulinum toxin products are not identical, and the dose equivalence has been debated for several years. In the year 2000, our clinic changed the recommended botulinum toxin product from Botox to Dysport for the treatment of cervical dystonia. Based on published reports, where dose con...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182711fc0

    authors: Rystedt A,Nyholm D,Naver H

    更新日期:2012-11-01 00:00:00

  • Metabolic and hormonal effects of dexfenfluramine on stress situations.

    abstract::Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Brindley DN

    更新日期:1988-01-01 00:00:00

  • First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease.

    abstract::The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-200305000-00011

    authors: Jhee SS,Fabbri L,Piccinno A,Monici P,Moran S,Zarotsky V,Tan EY,Frackiewicz EJ,Shiovitz T

    更新日期:2003-05-01 00:00:00

  • Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis.

    abstract:OBJECTIVES:The high incidence of fibrotic cardiac valvulopathies reported in association with the 8beta-ergoline dopamine (DA) agonist, pergolide, and also case reports for cabergoline and bromocriptine have made it necessary to review the theoretical basis and actual findings in the case of another DA agonist, the 8al...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00002826-200603000-00005

    authors: Hofmann C,Penner U,Dorow R,Pertz HH,Jähnichen S,Horowski R,Latté KP,Palla D,Schurad B

    更新日期:2006-03-01 00:00:00

  • Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.

    abstract:OBJECTIVE:Multiple sclerosis (MS) is a degenerative neurological condition that results in impairments in multiple domains including cognition, fatigue, and mood. Dalfampridine-extended release (D-ER) has been approved to improve walking in persons with MS. It is plausible that D-ER could improve cognition, fatigue, an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000130

    authors: Triche EW,Ruiz JA,Olson KM,Lo AC

    更新日期:2016-03-01 00:00:00

  • Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.

    abstract::The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00002826-200003000-00007

    authors: Jorga KM,Davis TL,Kurth MC,Saint-Hilaire MH,LeWitt PA,Fotteler B,Zürcher G,Rabbia M

    更新日期:2000-03-01 00:00:00